Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity
Advanced Science · 2025
DOI: 10.1002/advs.202506791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Amirhossein Bahreyni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada. Hauptthemen laut MEDLINE: Cancer Vaccines, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer vaccines emerge as a promising approach in immunotherapy, but their efficacy is often hindered by immunosuppressive factors like PD‐L1 on tumor cell membranes. To address this challenge, a personalized nanovaccine is developed using membranes from Coxsackievirus B3 (CVB3)‐infected 4T1 breast cancer cells combined with heat‐deactivated CVB3 (hdCVB3) encapsulated in PLGA nanoparticles (PLGA@hdCVB3I4T1M). RNA sequencing reveals significant upregulation of immune activation‐related genes, while protein analysis demonstrates reduced immunosuppressive markers (PD‐L1, B7‐H3, CD47) and increased immunostimulatory proteins (calreticulin), enhancing immune cell uptake and activation. In vitro and in vivo studies confirm the safety and potent immunostimulatory effects of PLGA@hdCVB3I4T1M, leading to enhanced immune cell infiltration, elevated proinflammatory cytokine production, and robust antitumor responses. The nanovaccine significantly improves tumor suppression and prolongs survival in animal models. Additionally, the inclusion of hdCVB3 amplified immune recognition of both viral and tumor antigens, further enhancing therapeutic efficacy, particularly when combined with oncolytic virotherapy. Mechanistically, this strategy primes the immune system for a more effective and sustained antitumor response. In summary, PLGA@hdCVB3I4T1M effectively stimulates the immune system, overcoming tumor immune evasion. This nanovaccine represents a promising strategy for enhancing cancer immunotherapy and holds strong potential for clinical translation, particularly in combination with oncolytic virotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
- Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
- Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
ORCID-Profile: Honglin Luo
Zitieren
APA
Bahreyni, A., Mohamud, Y., Singh, A., Banijamali, R. S., Tang, J., Zhang, J., & Luo, H. (2025). Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity. Advanced Science. https://doi.org/10.1002/advs.202506791
Vancouver
Bahreyni A, Mohamud Y, Singh A, Banijamali RS, Tang J, Zhang J, et al. Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity. Advanced Science. 2025. doi:10.1002/advs.202506791
BibTeX
@article{Bahreyni2025,
author = {Bahreyni, Amirhossein and Mohamud, Yasir and Singh, Amrit and Banijamali, Razieh Sadat and Tang, Jeffrey and Zhang, Jingchun and Luo, Honglin},
title = {Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202506791}
}
EUVIMED